Cargando…

Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis

Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more im...

Descripción completa

Detalles Bibliográficos
Autores principales: Baygan, Arjang, Aronsson-Kurttila, Wictor, Moretti, Gianluca, Tibert, Babylonia, Dahllöf, Göran, Klingspor, Lena, Gustafsson, Britt, Khoein, Bita, Moll, Guido, Hausmann, Charlotta, Svahn, Britt-Marie, Westgren, Magnus, Remberger, Mats, Sadeghi, Behnam, Ringden, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504152/
https://www.ncbi.nlm.nih.gov/pubmed/28744284
http://dx.doi.org/10.3389/fimmu.2017.00795
_version_ 1783249227643617280
author Baygan, Arjang
Aronsson-Kurttila, Wictor
Moretti, Gianluca
Tibert, Babylonia
Dahllöf, Göran
Klingspor, Lena
Gustafsson, Britt
Khoein, Bita
Moll, Guido
Hausmann, Charlotta
Svahn, Britt-Marie
Westgren, Magnus
Remberger, Mats
Sadeghi, Behnam
Ringden, Olle
author_facet Baygan, Arjang
Aronsson-Kurttila, Wictor
Moretti, Gianluca
Tibert, Babylonia
Dahllöf, Göran
Klingspor, Lena
Gustafsson, Britt
Khoein, Bita
Moll, Guido
Hausmann, Charlotta
Svahn, Britt-Marie
Westgren, Magnus
Remberger, Mats
Sadeghi, Behnam
Ringden, Olle
author_sort Baygan, Arjang
collection PubMed
description Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 10(6) DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy.
format Online
Article
Text
id pubmed-5504152
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55041522017-07-25 Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis Baygan, Arjang Aronsson-Kurttila, Wictor Moretti, Gianluca Tibert, Babylonia Dahllöf, Göran Klingspor, Lena Gustafsson, Britt Khoein, Bita Moll, Guido Hausmann, Charlotta Svahn, Britt-Marie Westgren, Magnus Remberger, Mats Sadeghi, Behnam Ringden, Olle Front Immunol Immunology Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 10(6) DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy. Frontiers Media S.A. 2017-07-11 /pmc/articles/PMC5504152/ /pubmed/28744284 http://dx.doi.org/10.3389/fimmu.2017.00795 Text en Copyright © 2017 Baygan, Aronsson-Kurttila, Moretti, Tibert, Dahllöf, Klingspor, Gustafsson, Khoein, Moll, Hausmann, Svahn, Westgren, Remberger, Sadeghi and Ringden. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Baygan, Arjang
Aronsson-Kurttila, Wictor
Moretti, Gianluca
Tibert, Babylonia
Dahllöf, Göran
Klingspor, Lena
Gustafsson, Britt
Khoein, Bita
Moll, Guido
Hausmann, Charlotta
Svahn, Britt-Marie
Westgren, Magnus
Remberger, Mats
Sadeghi, Behnam
Ringden, Olle
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title_full Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title_fullStr Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title_full_unstemmed Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title_short Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
title_sort safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504152/
https://www.ncbi.nlm.nih.gov/pubmed/28744284
http://dx.doi.org/10.3389/fimmu.2017.00795
work_keys_str_mv AT bayganarjang safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT aronssonkurttilawictor safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT morettigianluca safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT tibertbabylonia safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT dahllofgoran safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT klingsporlena safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT gustafssonbritt safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT khoeinbita safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT mollguido safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT hausmanncharlotta safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT svahnbrittmarie safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT westgrenmagnus safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT rembergermats safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT sadeghibehnam safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis
AT ringdenolle safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis